Your browser doesn't support javascript.
loading
[Predictive and prognostic value of monitoring lymphocyte subsets in peripheral blood before and after chemotherapy in patients with metastatic breast cancer].
Shao, B; Li, H P; DI, L J; Song, G H; Jiang, H F; Liang, X; Wang, C Y; Yan, Y; Lin, X L; Wang, L N; Wan, F L; Yuan, Y H; You, M N.
Afiliación
  • Shao B; Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Li HP; Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • DI LJ; Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Song GH; Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Jiang HF; Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Liang X; Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Wang CY; Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Yan Y; Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Lin XL; Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Wang LN; Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Wan FL; Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Yuan YH; Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • You MN; Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
Beijing Da Xue Xue Bao Yi Xue Ban ; 48(2): 304-9, 2016 Apr 18.
Article en Zh | MEDLINE | ID: mdl-27080286
ABSTRACT

OBJECTIVE:

To detect the proportion of lymphocyte subsets in peripheral blood of the advanced breast cancer patients before and after chemotherapy with docetaxel and thiotepa, as well as the association between the proportion of peripheral blood lymphocyte subsets with the response rate and prognosis.

METHODS:

The proportions of lymphocyte subsets (CD3+ T cell, CD3+/CD4+ T cell, CD3+/CD8+ T cell, CD3-/CD16+56+ NK cell, CD3+/CD16+56+ T cell, CD19+ B cell, CD4+/CD25+ T cell, CD8+/CD28- T cell, CD8+/CD28+ T cell) in the peripheral blood of 86 patients were analyzed with flowcytometry before and after chemotherapy. The result was analyzed in combination with clinicopathological data.

RESULTS:

The proportion of regulatory T cells (Treg) after chemotherapy in the disease control patients decreased significantly compared with that of the progressive patients (P=0.034). The difference of the proportions of Treg before and after chemotherapy affected significantly the overall survival (OS). The OS of the patients with decreased proportion of Treg was significantly longer than that of the patients with increased proportion of Treg, which was 23.5 and 9.4 months respectively (P<0.05).

CONCLUSION:

The patients with decreased proportion of Treg after chemotherapy had higher response rate and better survival benefit.
Asunto(s)
Buscar en Google
Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Subgrupos de Linfocitos T / Linfocitos T Reguladores Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: Zh Revista: Beijing Da Xue Xue Bao Yi Xue Ban Asunto de la revista: MEDICINA Año: 2016 Tipo del documento: Article País de afiliación: China
Buscar en Google
Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Subgrupos de Linfocitos T / Linfocitos T Reguladores Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: Zh Revista: Beijing Da Xue Xue Bao Yi Xue Ban Asunto de la revista: MEDICINA Año: 2016 Tipo del documento: Article País de afiliación: China